DNA fragements in molecules of cells
Epigenetic ENL-YEATS pathway shown to play a key role in development of some cancers. Company to develop cutting-edge therapeutics for treatment of AML and Wilms Tumor

NEW YORK, NEW YORK – March 16, 2020

Bridge Medicines and The Rockefeller University today announced an exclusive license agreement to develop novel inhibitors of ENL-YEATS for the treatment of acute leukemias such as Acute Myelogenous Leukemia (AML) and potentially solid tumors.

ENL-YEATS is an epigenetic “reader” protein that emerged from breakthrough science conducted in the laboratory of Lasker Award winner C. David Allis, Ph.D. The work was led by scientist Liling Wan, Ph.D., who was a postdoctoral fellow in the Allis lab at the time. Dr. Allis is the Joy and Jack Fishman Professor, Laboratory of Chromatin Biology and Epigenetics; Dr. Wan was recently appointed Assistant Professor of Cancer Biology and Assistant Investigator of the Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania.